Life Sciences Viral Vector Manufacturing Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Viral Vector Manufacturing Solutions
1.1 - About Life Sciences Viral Vector Manufacturing Solutions sector
Companies in the Life Sciences Viral Vector Manufacturing Solutions category provide technologies and services for designing, producing, and testing viral vectors used in gene therapy, including AAV, lentiviral, and adenoviral systems. They enable sponsors to move from preclinical development through GMP manufacturing with scalable processes, robust analytics, and regulatory support. Strategic buyers in viral vector manufacturing typically combine platform IP with compliant production capacity.
These providers offer vector design and capsid engineering, plasmid DNA generation, upstream production in HEK293 and other cell systems across adherent and suspension bioreactors, and downstream purification using chromatography and tangential flow filtration. They deliver GMP process development, scale-up, and tech transfer, along with QC analytics such as titer, impurity, and potency assays. Many provide sterile fill-finish, stability programs, and bioinformatics tools to optimize payload packaging and transduction efficiency.
Primary customers include biopharma gene therapy sponsors, cell and gene therapy developers, and academic translational labs. Outcomes delivered include faster IND/CTA readiness through validated processes, higher vector yields and consistency at scale, reduced cost of goods via optimized purification and production, and improved product quality supported by comprehensive GMP compliance and release testing. These vendors de-risk manufacturing and accelerate clinical timelines.
2. Buyers in the Life Sciences Viral Vector Manufacturing Solutions sector
2.1 Top strategic acquirers of Life Sciences Viral Vector Manufacturing Solutions companies
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage genetic medicine therapies built on a proprietary Therapeutic Vector Evolution platform that creates customized AAV vectors and supports a diverse pipeline of gene therapy candidates aimed at treating large-market and rare diseases.
- Key Products:
- Therapeutic Vector Evolution platform: Combines directed evolution with ~1 billion synthetic capsid sequences to engineer AAV vectors that efficiently transduce target tissues while reducing immunogenicity
- 4D-125: A Phase 1/2 gene therapy candidate employing evolved AAV vectors to treat X-linked retinitis pigmentosa by delivering therapeutic genes via routine, minimally invasive ocular administration
- 4D-110: Phase 1 gene therapy designed for choroideremia, using targeted AAV capsids to reach diseased retinal cells and correct underlying genetic defects
- 4D-310: Phase 1/2 gene therapy for Fabry disease that delivers corrective genes to cardiac tissue through evolved vectors intended to overcome pre-existing antibodies and improve cardiac function.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Viral Vector Manufacturing Solutions sector
M&A buyer group 1: Gene Therapy
32 companies
View group →
Description: Companies in Life Sciences Gene Therapy Platforms design, develop, and support gene-based therapeutics from vector engineering through GMP manufacturing and clinical readiness. Strategic buyers in this category typically blend platform technologies with CDMO capabilities to reduce technical risk and accelerate timelines. They enable sponsors to advance safe, scalable gene therapies with compliant processes, robust characterization, and translational data for regulatory milestones and eventual commercialization.
Sarepta Therapeutics
- Type: N/A
- Employees: ●●●●●
- Description: Provider of precision genetic medicines that discover, develop and commercialize gene therapies and exon-skipping RNA treatments for rare neuromuscular diseases, with a core focus on Duchenne muscular dystrophy and a growing pipeline addressing limb-girdle muscular dystrophy and other genetic disorders.
- Key Products:
- ELEVIDYS: FDA-approved one-time gene therapy delivering micro-dystrophin to Duchenne patients
- approved for ambulant children ≥4 yrs and accelerated approval for non-ambulatory, restoring dystrophin function and treating over 80 % of U.S. DMD population
- PMO Franchise (EXONDYS 51
- VYONDYS 53
- AMONDYS 45): proprietary morpholino oligonucleotide exon-skipping drugs that generated $249 M Q3-24 revenue, providing RNA-based therapy options for multiple Duchenne mutations
- SRP-9003 Gene Therapy: AAV-based treatment for Limb-Girdle Muscular Dystrophy type 2E with BLA filing planned 2025, aiming for accelerated approval by leveraging ELEVIDYS data
- siRNA Pipeline (Arrowhead collaboration): multi-program small-interfering RNA platform targeting neuromuscular
- CNS, cardiomyopathy and pulmonary indications to deliver multiple potential blockbuster launches before decade-end.
🔒
🔒
🔒
View all 32 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Viral Vector Manufacturing Solutions sector
3.1 - Buyout funds in the Life Sciences Viral Vector Manufacturing Solutions sector
2.2 - Strategic buyer groups for Life Sciences Viral Vector Manufacturing Solutions sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Viral Vector Manufacturing Solutions companies
4.2 - Public trading comparable groups for Life Sciences Viral Vector Manufacturing Solutions sector
Valuation benchmark group 1: Biopharma Research Tools and CDMOs
10 companies
View group →
Description: This public trading comparables group comprises biopharma service providers and tools vendors that enable discovery, development, and manufacturing of biologics and gene therapies. Business models span outsourced CRO/CDMO services and sale of critical bioprocess equipment, consumables, and analytics. They are comparable for valuation because revenues are tied to pipeline progression, cGMP capacity, and recurring supply contracts, with specialized know-how and regulatory compliance differentiating scale and margins.
Lonza Group
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of comprehensive services and products focusing on the discovery, development, and manufacturing of active pharmaceutical ingredients, biologics, and innovative dosage forms for the pharmaceutical, biotech, and consumer health industries to support the commercialization of various therapies, with a strong commitment to sustainability and zero-incident workplace initiatives.
- Key Products:
- Bioscience Products: Tools and technologies for cell culture, research, and quality control in biomanufacturing
- Capsule Manufacturing: Pharmaceutical services ensuring high-quality capsule products using gelatin, HPMC, or pullulan
- Biologics Manufacturing: Custom development and manufacturing services for biologics from late phase drug discovery to market supply
- API Development: Early phase discovery and manufacturing of active pharmaceutical ingredients for various therapeutic areas
- Healthcare Solutions: Innovative dosage forms and customized solutions for the pharma and consumer health industries.
🔒
🔒
🔒
View all 10 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →